Your browser doesn't support javascript.
loading
Humoral Immunogenicity of 3 COVID-19 Messenger RNA Vaccine Doses in Patients With Inflammatory Bowel Disease.
Schell, Trevor L; Knutson, Keith L; Saha, Sumona; Wald, Arnold; Phan, Hiep S; Almasry, Mazen; Chun, Kelly; Grimes, Ian; Lutz, Megan; Hayney, Mary S; Farraye, Francis A; Caldera, Freddy.
  • Schell TL; Department of Medicine, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA.
  • Knutson KL; Department of Immunology, Mayo Clinic Jacksonville, Jacksonville, FL, USA.
  • Saha S; Department of Medicine, Division of Gastroenterology & Hepatology, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA.
  • Wald A; Department of Medicine, Division of Gastroenterology & Hepatology, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA.
  • Phan HS; Department of Medicine, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA.
  • Almasry M; Department of Medicine, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA.
  • Chun K; Labcorp, R&D and Specialty Medicine, Burlington, NC, USA.
  • Grimes I; Department of Medicine, Division of Gastroenterology & Hepatology, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA.
  • Lutz M; Department of Medicine, Division of Gastroenterology & Hepatology, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA.
  • Hayney MS; School of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA.
  • Farraye FA; Inflammatory Bowel Disease Center, Division of Gastroenterology & Hepatology, Mayo Clinic, Jacksonville, FL, USA.
  • Caldera F; Department of Medicine, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA.
Inflamm Bowel Dis ; 28(11): 1781-1786, 2022 11 02.
Article en En | MEDLINE | ID: mdl-35396992
Herein, we evaluated the humoral immunogenicity of a third coronavirus disease 2019 messenger RNA vaccine dose in patients with inflammatory bowel diseases. All patients displayed a humoral immune response, and median antibody concentrations were higher after the third dose than after completion of the 2-dose series.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedades Inflamatorias del Intestino / Colitis Ulcerosa / COVID-19 Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedades Inflamatorias del Intestino / Colitis Ulcerosa / COVID-19 Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article